This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Certificate of Mailing: Date of Deposit: February

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313/1450.

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Fabien Schweighoffer et al.

Art Unit:

1637

Serial No.:

09/623,828

Examiner:

J. Siew

Filed:

November 30, 2000

Customer No.:

21559

Title:

QUALITATIVE DIFFERENTIAL SCREENING

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 1.321 and 3.73(b)

Pursuant to 37 C.F.R. § 1.321(b), ExonHit Therapeutics S.A., the assignee of the entire right, title, and interest in the above-referenced application seeks to disclaim the terminal portion of the term of the patent to be granted on the application. This terminal disclaimer is binding on the grantee and its successors or assigns.

Pursuant to 37 C.F.R. § 1.321(b)(1), this terminal disclaimer is signed by an attorney of record.

Pursuant to 37 C.F.R. § 1.321(b)(2), ExonHit Therapeutics S.A., hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the aboveidentified application subsequent to the expiration date of U.S. Patent No. 6,251,590. ExonHit Therapeutics S.A. does not disclaim any terminal part of any patent granted on the above-

02/10/2004 DEMMANUI 00000126 09623828

identified application prior to the expiration date of the full statutory term of U.S. Patent No. 6,251,590 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated below.

Pursuant to 37 C.F.R. § 1.321(b)(3) and § 3.73(b), the undersigned attorney of record certifies that ExonHit Therapeutics S.A., a corporation, is the assignee of the entire right, title, and interest in the above application by virtue of:

■ An assignment from the inventors of the application. The assignment was recorded in the Patent and Trademark Office at Reel/Frame 011364/0736 on December 4, 2000. A copy of the assignment is attached.

The undersigned attorney of record has reviewed all the documents in the chain of title of the above-referenced application and to the best of the undersigned's knowledge and belief, title is in ExonHit Therapeutics S.A.

Pursuant to 37 C.F.R. § 1.321(b)(4), enclosed is a check for \$ 55.00 for the fee set forth in 37 C.F.R. § 1.20(d).

Further, pursuant to 37 C.F.R. § 1.321(c)(3), this terminal disclaimer is filed to obviate a double patenting rejection in the above-referenced patent application. Any patent granted on the above-referenced application or any resulting patent subject to reexamination proceedings shall be enforceable only for and during such period that said patent is commonly owned with the application or patent which formed the basis for the rejection.

If there are any additional charges, or any credits, please apply them to Deposit Account Number 03-2095.

Respectfully submitted?

Date: Myung 3, W

g

Kristina Bieker-Brady, Ph.D., P.C.


Reg. No. 39,109

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

F:\50146\50146.004002 Terminal Disclaimer.doc








UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

PTAS



101560880A



CLARK & ELBING LLP KRISTINA BIEKER-BRADY, PH.D 176 FEDERAL STREET BOSTON, MA 02110

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 12/04/2000

REEL/FRAME: 011364/0736

NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

SCHWEIGHOFFER, FABIEN

DOC DATE: 10/26/2000

ASSIGNOR:

BRACCO, LAURENT

DOC DATE: 10/26/2000

ASSIGNOR:

TOCQUE, BRUNO

DOC DATE: 10/26/2000

ASSIGNEE:

EXONHIT THERAPEUTICS S.A. 63-65 BOULEVARD MASSENA 6503 PARIS, FRANCE

SERIAL NUMBER: 09623828

PATENT NUMBER:

FILING DATE: 11/30/2000

ISSUE DATE:

SHARON BROOKS, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS